Drugs / EBDTKN-401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07627698 | Mar 2026 → Jun 2027 expected | cutaneous melanoma, uveal melanoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBDTKN-401 | “EBDTKN-401 is an allogeneic donor-derived NK-cell product engineered with an OR-gate/tandem CAR recognizing CSPG4 or GD2 and an inducible caspase-9 safety switch.” NCT07627698 ↗ |
| Action | Deplete | “These cells recognize tumor antigens and induce targeted cytotoxicity” NCT07627698 ↗ |
| Modality | Cell therapy | “Genetically engineered natural killer (NK) cells expressing dual chimeric antigen receptors targeting CSPG4 and GD2 are expanded ex vivo and infused (IV) into patients.” NCT07627698 ↗ |
| Route | Intravenous | “expanded ex vivo and infused (IV) into patients” NCT07627698 ↗ |